Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nordic Nanovector ASA ( (DE:8NN) ) has issued an announcement.
Thor Medical ASA has successfully completed a private placement and a retail offering, raising a total of NOK 86.4 million in gross proceeds. This capital increase has been registered with the Norwegian Register of Business Enterprises, resulting in a new share capital of NOK 69,797,184, divided into 348,985,920 shares. This financial maneuver is likely to strengthen Thor Medical’s operational capabilities and market positioning in the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in the production of radionuclides, primarily alpha particle emitters derived from naturally occurring thorium. The company utilizes a proprietary production process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is based in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange under the ticker ‘TRMED’.
Average Trading Volume: 2,133,987
Current Market Cap: NOK778.2M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.